We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+12.67%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$701M
AUM Growth
+$112M
Cap. Flow
+$22.9M
Cap. Flow %
3.26%
Top 10 Hldgs %
45.26%
Holding
159
New
30
Increased
40
Reduced
26
Closed
28

Top Buys

Rank Stock Value
1
CEL
Cellcom Israel, Ltd.
CEL
+$14.1M
2
AGN
Allergan plc
AGN
+$14M
3
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$9M
4
MRK icon
Merck
MRK
+$6.67M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$6.17M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$16M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13.8M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.99M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.63M

Sector Composition

Rank Sector Weight
1 Healthcare 65.28%
2 Miscellaneous 21.58%
3 Technology 5.67%
4 Communication Services 4.68%
5 Industrials 1.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
126
PUT
DELISTED
Sage Therapeutics
SAGE
$150K 0.02%
+2,400
New +$188K
XRAY icon
127
Dentsply Sirona
XRAY
$1.87B
$150K 0.02%
2,500
– –
VSTO
128
DELISTED
Vista Outdoor Inc.
VSTO
$138K 0.02%
6,000
– –
CMG icon
129
Chipotle Mexican Grill
CMG
$42.4B
$123K 0.02%
20,000
– –
ATHX
130
DELISTED
Athersys, Inc. Common Stock
ATHX
$2K ﹤0.01%
+31
New +$1.4K
ALNY icon
131
Alnylam Pharmaceuticals
ALNY
$32.9B
– –
-50,000
Closed -$3.99M
BCLI
132
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-55,576
Closed -$2.76M
BIIB icon
133
CALL
Biogen
BIIB
$32.4B
– –
-500
Closed -$14.5M
BMY icon
134
Bristol-Myers Squibb
BMY
$128B
– –
-248,000
Closed -$13.8M
CAMT icon
135
Camtek
CAMT
$6.73B
– –
-99,035
Closed -$478K
DBVT
136
DBV Technologies
DBVT
$786M
– –
-9,017
Closed -$3.22M
FLEX icon
137
Flex
FLEX
$40.3B
– –
-125,402
Closed -$1.54M
CBIO
138
Crescent Biopharma
CBIO
$623M
– –
-3,208
Closed -$3.58M
LRCX icon
139
Lam Research
LRCX
$337B
– –
-168,600
Closed -$2.38M
NVMI
140
Nova
NVMI
$11.1B
– –
-13,844
Closed -$306K
NVS icon
141
Novartis
NVS
$268B
– –
-223,200
Closed -$16M
OEF icon
142
CALL
iShares S&P 100 ETF
OEF
$20.3B
– –
-100
Closed -$1.42M
PTN
143
Palatin Technologies
PTN
$18.6M
– –
-377
Closed -$203K
QQQ icon
144
PUT
Invesco QQQ Trust
QQQ
$482B
– –
-1,200
Closed -$17.2M
TMO icon
145
Thermo Fisher Scientific
TMO
$243B
– –
-11,688
Closed -$2.04M
TSEM icon
146
Tower Semiconductor
TSEM
$24.8B
– –
-67,155
Closed -$1.6M
WAB icon
147
Wabtec
WAB
$47.1B
– –
-16,600
Closed -$1.52M
XNTK icon
148
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.91B
– –
-5,566
Closed -$43.5M
MRNS
149
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-332,855
Closed -$1.82M
SGEN
150
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-36,000
Closed -$1.86M
3 4 5
6
7

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sphera Funds Management held 159 positions worth $701M, up 19% from $589M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $22.9M of net new capital in Q3 2017, opening 30 new positions and adding to 40 existing holdings. Its largest new stake was Cellcom Israel, Ltd.: 1,535,988 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 68% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Caesarstone, an estimated $3.28M trimmed.

  • Sphera Funds Management's largest Q3 2017 buy was Cellcom Israel, Ltd.: 1,535,988 shares worth $14.3M.
  • Sphera Funds Management added most to Merck in Q3 2017, an estimated $6.67M increase.
  • Sphera Funds Management's biggest Q3 2017 reduction was Caesarstone, cutting an estimated $3.28M.
  • Sphera Funds Management fully exited Novartis in Q3 2017, selling an estimated $16M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $701M portfolio in Q3 2017.
  • Sphera Funds Management opened 30 new positions and closed 28 in Q3 2017.
  • Sphera Funds Management's portfolio value rose 19% quarter-over-quarter to $701M.

Based on Sphera Funds Management's 13F filing for Q3 2017, filed 9 Nov 2017.